Temafloxacin: Difference between revisions
m (Protected "Temafloxacin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
'''Temafloxacin''' (marketed by [[Abbott Laboratories]] as '''Omniflox'''), is a [[fluoroquinolone]] [[antibiotic]] drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths. | '''Temafloxacin''' (marketed by [[Abbott Laboratories]] as '''Omniflox'''), is a [[fluoroquinolone]] [[antibiotic]] drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths. | ||
| Line 14: | Line 14: | ||
[[Category:Fluoroquinolone antibiotics]] | [[Category:Fluoroquinolone antibiotics]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:42, 20 August 2012
|
WikiDoc Resources for Temafloxacin |
|
Articles |
|---|
|
Most recent articles on Temafloxacin Most cited articles on Temafloxacin |
|
Media |
|
Powerpoint slides on Temafloxacin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Temafloxacin at Clinical Trials.gov Clinical Trials on Temafloxacin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Temafloxacin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Temafloxacin Discussion groups on Temafloxacin Patient Handouts on Temafloxacin Directions to Hospitals Treating Temafloxacin Risk calculators and risk factors for Temafloxacin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Temafloxacin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Temafloxacin (marketed by Abbott Laboratories as Omniflox), is a fluoroquinolone antibiotic drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths.
Omniflox was approved to treat lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections in the U.S. by the Food and Drug Administration in January 1992. Severe adverse reactions, including allergic reactions and hemolytic anemia, developed in about fifty patients during the first four months of its use, leading to three patient deaths. Abbott withdrew the drug from sale in June 1992.
External links
- FDA press release June 5, 1992.